Connection

Co-Authors

This is a "connection" page, showing publications co-authored by WALDEMAR PRIEBE and AMY B HEIMBERGER.
Connection Strength

2.090
  1. Small molecular inhibitors of p-STAT3: novel agents for treatment of primary and metastatic CNS cancers. Recent Pat CNS Drug Discov. 2008 Nov; 3(3):179-88.
    View in: PubMed
    Score: 0.342
  2. A first-in-human Phase I trial of the oral p-STAT3 inhibitor WP1066 in patients with recurrent malignant glioma. CNS Oncol. 2022 06 01; 11(2):CNS87.
    View in: PubMed
    Score: 0.219
  3. Radiation with STAT3 Blockade Triggers Dendritic Cell-T cell Interactions in the Glioma Microenvironment and Therapeutic Efficacy. Clin Cancer Res. 2020 09 15; 26(18):4983-4994.
    View in: PubMed
    Score: 0.192
  4. Profiles of brain metastases: Prioritization of therapeutic targets. Int J Cancer. 2018 12 01; 143(11):3019-3026.
    View in: PubMed
    Score: 0.170
  5. Therapeutic targets in subependymoma. J Neuroimmunol. 2014 Dec 15; 277(1-2):168-75.
    View in: PubMed
    Score: 0.130
  6. The tumor microenvironment expression of p-STAT3 influences the efficacy of cyclophosphamide with WP1066 in murine melanoma models. Int J Cancer. 2012 Jul 01; 131(1):8-17.
    View in: PubMed
    Score: 0.104
  7. Hypoxia potentiates glioma-mediated immunosuppression. PLoS One. 2011 Jan 20; 6(1):e16195.
    View in: PubMed
    Score: 0.100
  8. Intratumoral mediated immunosuppression is prognostic in genetically engineered murine models of glioma and correlates to immunotherapeutic responses. Clin Cancer Res. 2010 Dec 01; 16(23):5722-33.
    View in: PubMed
    Score: 0.098
  9. Glioma cancer stem cells induce immunosuppressive macrophages/microglia. Neuro Oncol. 2010 Nov; 12(11):1113-25.
    View in: PubMed
    Score: 0.097
  10. Inhibition of p-STAT3 enhances IFN-alpha efficacy against metastatic melanoma in a murine model. Clin Cancer Res. 2010 May 01; 16(9):2550-61.
    View in: PubMed
    Score: 0.095
  11. Glioblastoma cancer-initiating cells inhibit T-cell proliferation and effector responses by the signal transducers and activators of transcription 3 pathway. Mol Cancer Ther. 2010 Jan; 9(1):67-78.
    View in: PubMed
    Score: 0.093
  12. The role of tregs in human glioma patients and their inhibition with a novel STAT-3 inhibitor. Clin Neurosurg. 2009; 56:98-106.
    View in: PubMed
    Score: 0.087
  13. The incidence, correlation with tumor-infiltrating inflammation, and prognosis of phosphorylated STAT3 expression in human gliomas. Clin Cancer Res. 2008 Dec 15; 14(24):8228-35.
    View in: PubMed
    Score: 0.086
  14. A novel phosphorylated STAT3 inhibitor enhances T cell cytotoxicity against melanoma through inhibition of regulatory T cells. Cancer Immunol Immunother. 2009 Jul; 58(7):1023-32.
    View in: PubMed
    Score: 0.086
  15. A novel inhibitor of signal transducers and activators of transcription 3 activation is efficacious against established central nervous system melanoma and inhibits regulatory T cells. Clin Cancer Res. 2008 Sep 15; 14(18):5759-68.
    View in: PubMed
    Score: 0.085
  16. A novel small molecule inhibitor of signal transducers and activators of transcription 3 reverses immune tolerance in malignant glioma patients. Cancer Res. 2007 Oct 15; 67(20):9630-6.
    View in: PubMed
    Score: 0.080
  17. Signal transducer and activator of transcription 3 promotes angiogenesis and drives malignant progression in glioma. Neuro Oncol. 2012 Sep; 14(9):1136-45.
    View in: PubMed
    Score: 0.028
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.